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Phosphotyrosine Prodrugs: Design, Synthesis and Anti-STAT3 
Activity of ISS-610 Aryloxy Triester Phosphoramidate Prodrugs‡ 
Ageo Miccoli,a Binar A. Dhiani, a and Youcef Mehellou*a
Unmasked phohate groups of phosphotyrosine-containing molecules carry two negative charges at physiological pH, which 
compromise their (passive) cellular uptake. Also, these phosphate groups are often cleaved off by phosphatases. Together, 
these ultimately limit the pharmacological efficacy of the phosphotyrosine-containing compounds. To address these 
drawbacks, we herein present the application of the aryloxy triester phosphoramidate prodrug technology, a 
monophosphate prodrug technology, to the phosphotyrosine-containing compound ISS-610-Met, an analogue of the 
anticancer STAT3 dimerization inhibitor ISS-610. Our data shows that the generated ISS-610-Met prodrugs exhibited 
enhanced pharmacological activity and inhibition of STAT3 downstream signaling compared to the parent compound ISS-
610-Met and the known STAT3 dimerization inhibitor ISS-610. These encouraging results provide a compelling proof of 
concept for the potential of the aryloxy triester phosphoramidate prodrug technology in the discovery of novel therapeutics 
that contain phosphotyrosine and its phospho mimics.
1. Introduction
Phosphotyrosine mediates the formation of protein complexes by 
binding to various phosphotyrosine-binding domains such as Src 
homology 2 (SH2) domains,1 which are present in many proteins that 
include kinases, phosphatases and transcription factors. Given the 
vital roles SH2 domains play in mediating many cell signaling events 
that are implicated in the pathogenesis of human diseases,2-4 the 
targeting of these phosphotyrosine-binding domains by small 
molecules has been noted for a long time as a promising approach in 
drug discovery.5 However, the development of these molecules has 
largely been hindered by the requirement of a phosphotyrosine 
motif to mimic the endogenous moiety and achieve binding to the 
target proteins with high affinity. This is because the incorporation 
of phosphate groups makes these phosphotyrosine-containing 
molecules unstable in vivo due to dephosphorylation by alkyl 
phosphatases. Additionally, the charged phosphotyrosine species at 
physiological pH limit their (passive) cellular entry. To address these 
shortages, phosphate bioisosteres, e.g. carboxylic acids, have been 
used and this led to a series of compounds with interesting biological 
activities.5 However, none of these compounds have progressed to 
late clinical development. 
In order to improve the drug-like properties of phosphotyrosine-
containing molecules and their phospho-mimics, we hypothesized 
that this could be achieved by applying monophosphate prodrug 
technologies to these compounds. Although there are many prodrug 
strategies reported to be effective in delivering 
monophosphorylated molecules into cells, we decided to use the 
aryloxy triester phosphoramidate prodrug technology6 as this has 
already delivered two FDA-approved drugs and over 10 clinical 
candidates.7 In this prodrug technology, the monophosphate group 
is masked by an aryl motif and an amino acid ester (Fig. 1). The 
hydrolysis of these masking groups is now well understood to 
proceed in vivo via the involvement of two distinct enzymes; 
carboxypeptidase Y8 and a phosphoramidase-type enzyme (Hint-1)9 
(Fig. 1) [see Mehellou Y et al6 for a detailed account on the aryloxy 
triester prodrug technology].  
Figure 1. Metabolism of the aryloxy phosphoramidate prodrug 
technology to release the monophosphate species. 
To determine the suitability of the aryloxy triester phosphoramidate 
prodrug technology, we chose the STAT3 dimerization inhibitor ISS-
610, a peptidomimetic that contains a phosphotyrosine motif (Fig. 
2). ISS-610 was first reported in 2004 as a binder of a transcription 
factor known as the signal transducer and activator of transcription 
3 (STAT3).10 This molecule contains a phosphotyrosine moiety by 
design, which allows it to bind the SH2 domain of STAT3 resulting in 
the inhibition of its dimerization and downstream signaling. The 
interest in the discovery of small molecules that inhibit STAT3 is 
driven by the fact that STAT3 is constitutively active in numerous 
cancers and contributes to tumor cell proliferation and survival.11 At 
the molecular level, the activation of STAT3 involves phosphorylation 
by upstream kinases, which leads to its homo- and heterodimers with 
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other STAT isoforms. This dimerization is critical for its downstream 
signaling and thus the inhibition of this dimerization process 
emerged as a favorable approach in the discovery of anticancer 
STAT3 inhibitors. 
Figure 2. Chemical structure of the phosphotyrosine containing 
STAT3 dimerization inhibitor ISS-610. 
ISS-610 was found to be able to inhibit the binding of STAT3 to the 
target DNA with moderate efficacy, IC50 = 42 μM.10  Although cellular 
data also supported the ability of ISS-610 to inhibit STAT3 
dimerization and subsequent downstream signaling, the 
concentrations required to achieve these in cells were relatively high 
(~ 1 mM).10 We suspected that this was due to poor cellular uptake 
of ISS-610 that results from its relatively large size, charged nature at 
physiological pH and dephosphorylation of the phosphotyrosine 
moiety. These limitations made ISS-610 an ideal candidate for the 
application of the powerful monophosphate prodrug technology, the 
aryloxy triester phosphoramidate technology.  
2. Results and Discussion
2.1. Synthesis of ISS-610 and its prodrugs 
In the design of ISS-610 phosphoramidate prodrugs, the carboxylic 
acid of ISS-610 had to be protected to avoid a nucleophilic attack 
from the free carboxylate group onto the phosphorous atom leading 
to the breakdown of the prodrug motif akin to its in vivo metabolism. 
Thus, ISS-610 prodrugs presented in this work carry a methyl group 
that blocks the C-terminal carboxylic group of the L-leucine amino 
acid, a compound we termed ISS-610-Met. As a control, we also 
synthesised the ISS-610-Met monophosphate (7) (Figure 3). Notably, 
modifications of ISS-610 in its C-terminal region have been 
extensively explored and led to the discovery of potent STAT3 
dimerization inhibitors.12 
The synthesis of the ISS-610-Met started by the coupling of the Boc-
tyrosine (2) and L-leucine methyl ester via the use of the peptide 
coupling reagent benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) in the presence of triethylamine (TEA) 
to attain dipeptide 3 in a high yield (94%). Removal of the Boc-
protecting group with trifluoroacetic acid (TFA) afforded fragment 4  
in almost quantitative yield (99%) and this was subsequently coupled 
to 4-cyanobenzoyl chloride, which had been prepared as reported13. 
Subsequently, the phosphorodiamidate of compound 5 was 
synthesised by reacting intermediate 5 with N,N,N',N'-
tetramethylphosphorodiamidic chloride in the presence of DMAP 
and DBU to generate the desired product, 6, in a moderate yield, 
50%.12 Finally, the acidification diamidate 6 with TFA yielded acid ISS-
610-Met (7) in high yield, 76%.12
Next, we synthesised ISS-610-Met aryloxy triester phosphoramidate 
prodrugs (Figure 4), the phosphorochloridates were initially 
synthesised as previously reported.14, 15 Briefly, 1-napthol (8) in dry 
diethyl ether at -78 °C was treated with phosphorous oxychloride 
(POCl3) and TEA to afford phosphorodichloridate 9, which was used 
in the next step without purification. Subsequently, this was 
dissolved in anhydrous DCM and reacted with the desired L-amino 
acid esters in the presence of triethylamine to give the desired 
phosphorochloridates in excellent yields (70-97%). 
The coupling of the phosphorochloridates, 10-12, to the ISS-610-Met 
core structure, 5, was pursued in dry THF using triethylamine as a 
base. This gave the desired ISS-610-Met phosphoramidate prodrugs, 
13-15, in good yields (72-93%). Notably, the final prodrugs, 13-15, 
were generated as a mixture of two diastereoisomers due to the 
chiral phosphorous center and as indicated by the phosphorous 31P-
NMR of these compounds (see Supplementary Information). This is 
typical for the synthesis of aryloxy triester phosphoramidate 
prodrugs and many of these prodrugs are synthesised and studied as 
a mixture of diastereoisomers6 with some of them even undergoing 
(late) clinical trials in this form, e.g. NUC-103115.
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Figure 3. Synthesis of ISS-610-Met (7). Reagents and conditions: a) 
PyBop, L-leucine methyl ester hydrochloride, NEt3, THF, 94%; b) TFA, 
DCM, 99%; c) 4-cyanobenzoyl chloride, NEt3, THF, 42%; d) N,N,N',N'-
tetramethylphosphorodiamidic chloride, DMAP, DBU, THF, 50%; e) 
TFA, H2O, 76%. 
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Figure 4. Synthesis of ISS-610-Met aryloxy triester 
phosphoramidate prodrugs. Reagents and conditions: a) POCl3, TEA, 
diethyl ether, -78°C, 98%; b) for compound 10 (R = methyl): L-alanine methyl 
ester hydrochloride, TEA, DCM, -78 °C, 70%, for compound 11 (R = isopropyl): 
L-alanine isopropyl ester hydrochloride, TEA, DCM, -78 °C, 72%, for 
compound 12 (R = benzyl): L-alanine benzyl ester hydrochloride, TEA, DCM, -
78 °C, 97%; c) for compound 13 (R = methyl): phosphorochloridate 10, TEA, 
DCM, 72%,  for compound 14 (R = isopropyl): phosphorochloridate 11, TEA,
DCM, 91%, for compound 15 (R = benzyl): phosphorochloridate 12, TEA, DCM,
93%;
In the design of the aryloxy triester phosphoramidate prodrugs, the 
most common aryl motif used is the phenyl followed by naphthyl. In 
this work, we chose the naphthyl as the aryl motif of the prodrug 
moiety as it is a better leaving group than phenol and hence in the 
metabolism of the prodrugs the -P-O- bond would favor cleavage to 
release the 1-naphthol group (Option 1, Figure 5) instead of cleaving 
the bond to release the phenol of the phosphotyrosine (Option 2, 
Figure 5). Indeed, following entry to cells, the ester group of the 
aryloxy triester phosphoramidate prodrugs is cleaved off by 
esterases, e.g. carboxypeptidase Y, to yield an unmasked carboxylate 
group (16). This then performs a nucleophilic attack on the 
phosphorous center. This leads to the cleavage of one of the -O-P- 
phosphorous bonds as labelled options 1 and 2 in Figure 5. Thus, in 
this case, having a naphthyl group as a leaving group would favor 
option 1 and hence lead to the formation of the highly unstable 
anhydrous intermediate 17. This subsequently gets opened up by a 
nucleophilic attack from a water molecule on the phosphorous 
center generating phosphoramidate 18. Finally, a phosphoramidase-
type enzyme. E.g. Hint-1, cleaves the P-N bond to release the 
unmasked monophosphate 19, ISS-610-Met in this case.  
Figure 5. Postulated mechanism of aryloxy triester phosphoramidate 
prodrugs.6  
2.2. Serum stability and metabolism of ISS-610 prodrugs 
As compounds 13-15 are prodrugs, we initially studied their stability 
in human serum. For this prodrug 14 was incubated with human 
serum at 37 °C for 12 h and the mixture was monitored by 31P-NMR 
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Figure 6. Human serum stability of Prodrug 14. A: 31P-NMR scan of prodrug 14 in 0.15 mL DMSO and 0.15 mL D2O. dP = -1.43 and 0.93. B: 
Final 31P-NMR scan of the sample from A after being incubated with 0.3 mL of human serum at 37 °C for 12 h. C: LCMS trace of prodrug 14 
alone. The peak corresponding to the mass of the parent compound, 779.2750 g/mol (+Na), is highlighted in light yellow. D: LCMC trace the 
human serum alone. E: LCMS trace of the organic fraction of the sample of prodrug 14 after being incubated with 0.3 mL of human serum at 
37 °C for 12 h. The peak corresponding to the mass of the parent compound, 779.2750 g/mol (+Na), is highlighted in light yellow. 
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as we reported previously.14 At t = 0 h, two singlets appeared on the 
31P-NMR, dP = -1.43 and 0.93, which correspond to the two 
diastereoisomers of prodrug 13 (Figure 6). Upon the addition of the 
human serum and monitoring the reaction for 12 h, no new 
phosphorous peaks were detected indicating the stability of this 
prodrug in human serum. Although the intensity of the prodrug 
peaks at t = 12 h appeared lower than those at t = 0 h, this was due 
to some of the prodrug crashing out of solution following the 
addition of the serum (Figure 6). This is due to the relatively high 
lipophilicity of prodrug 13 (cLog P = 6.06). This is a common 
observation is studying these prodrugs when they have a relatively 
high lipophilicity. To further confirm the stability of prodrug 13, we 
run a mass spectrometry of the parent compound by itself and then 
the sample following 12 h incubation in human serum. The results 
showed that no new mass spectrometry peaks appeared following 
incubation with human serum for 12 h. This is a further confirmation 
of the stability of this prodrug in human serum for the 12 h studied.   
Notably, this stability profile is in line with the human serum stability 
profiles of the aryloxy triester phosphoramidate prodrugs of 
nucleoside monophosphates.14, 15  
2.3. Effect of ISS-610 and ISS-610-Met prodrugs on cancer cells  
The activation of the JAK/STAT3 signalling cascade leads to STAT3 
phosphorylation, dimerization and translocation to the nucleus 
where it mediates the transcription of anti-apoptotic genes such as 
Survivin and Bcl-xl.16 Hence, in determining the potency of our 
prodrugs’ inhibition of STAT3 dimerization, we probed for the 
expression levels of Survivin and Bcl-xl. For this, we chose the breast 
cancer cell line MDA-MB-468, which has the JAK/STAT3 signalling 
cascade constitutively active and is widely used in studying the 
biological activity of STAT3 inhibitors.17-19 Thus, the cells were 
treated with the parent compound ISS-610 (1) or its C-methylated 
derivative ISS-610-Met (7) as positive controls, or prodrugs 13-15 at 
the indicated concentrations for 24 hours. Following lysis, the cell 
lysates underwent Western blotting for total Survivin and Bcl-xl as a 
readout of the compound’s ability to inhibit STAT3 dimerization and 
downstream signalling. As shown in Figure 7, the parent compounds, 
ISS-610 and ISS-610-Met, did not have any significant 
downregulation of the expression of the anti-apoptotic proteins 
Survivin and Bcl-xl, which is in line with the poor cell activity of the 
ISS-610 peptidomimetic.10 However, prodrugs 13-15 showed more 
profound downregulation of the expression of Survivin and Bcl-xl. 
This was most notable with compounds 13 and 14, which exhibited 
significant reduction of Survivin even at 30 µM. In terms of the 
structure-activity relationship of aryloxy triester phosphoramidate 
prodrugs, the ones with benzyl ester tend to exhibit more potent 
biological activity than the ones with methyl and isopropyl esters.6 
However, in this work, the prodrugs with methyl and isopropyl 
esters, 13 and 14 respectively, exerted more potent activity than 
their prodrug counterpart with the benzyl ester, compound 15. This 
is most likely due to the relatively high lipophilicity of compound 15 
as compared to compounds 13 and 14, which could limit their 
solubility in the cell media. Indeed, in treating the cells with prodrugs 
13-15, only prodrug 15 upon addition to the cells resulted in a cloudy 
media, which rapidly cleared up after gentle shaking. Nevertheless, 
the observed downregulation of Survivin and Bcl-xl with prodrugs 13 
and 14 relative to the lack of any effect on these proteins by the 
parent compounds ISS-610 and ISS-610-Met was notable and 
indicates the potential of this prodrug approach in increasing the 
potency of phosphotyrosine-containing STAT3 dimerization 
inhibitors.
3. Conclusion
STAT3 dimerization is an essential process for its downstream 
signalling and cancer cell survival. The inhibition of this process using 
phosphotyrosine-containing small molecules that bind the STAT3 
SH2 domain is an attractive approach in treating cancer. As small 
molecules that contain phosphotyrosine and its phospho mimics 
often have poor cellular uptake, we herein described – as a proof of 
concept- the application of the aryloxy triester phosphoramidate 
approach to ISS-610-Met, an analogue of phosphotyrosine-
containing STAT3 dimerization inhibitor ISS-610. Our data showed 
that these prodrugs are stable in human serum at 37 °C for 12 h. In 
cells, these prodrugs were relatively more potent in inhibiting STAT3 
downstream signalling than their parent compounds ISS-610 and ISS-
610-Met. Collectively, this work highlights the novel applicability of 
the aryloxy triester phosphoramidate prodrug approach in 
discovering new therapeutics that contain phosphotyrosine- or its 
phospho mimics, an endeavour that has proved to be a stern 
challenge so far.
4. Experimental
General Information. Dichloromethane, diethyl ether, methanol, 
and toluene were dried in-house using a Pure Solv-MD solvent 
purification system. All the other solvents were used as received 
from commercial suppliers. All of the other reagents used in the 
synthesis were purchased from Sigma-Aldrich except L-alanine 
isopropyl ester, which was synthesised in house. ISS-610 was 
purchased from Alta Biosciences (Birmingham, UK) and it had a 
99.2% purity. All reactions were carried out under an argon 
atmosphere. Reactions were monitored with analytical TLC on silica 
gel 60-F254 precoated aluminum plates and visualized under UV (254 
nm) and/or with 31P NMR spectra. Column chromatography was 
performed on silica gel (35-70 μM). NMR data were recorded on a 
Bruker AV300, AVIII300, AV400, AVIII400, or DRX500 spectrometer in 
ISS-610 (µM) 15 (µM) 14 (µM) 13 (µM)
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Figure 7. Inhibition of the STAT3-dependent expression of the anti-apoptotic proteins Survivin and Bcl-xl by ISS-610 prodrugs. Cultured 
MDA-MB-468 cells were treated with DMSO (control), ISS-610, prodrugs 13-15 at the indicated concentrations for 24 h. The cell lysates 
subsequently underwent Western blotting for total STAT3, total Survivin and total Bcl-xl. Total b-actin was included as a loading control. 
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the deuterated solvents indicated, and the spectra were calibrated 
on residual solvent peaks. Chemical shifts (δ) are quoted in ppm, and 
J values are quoted in Hz. In reporting spectral data, the following 
abbreviations were used: s (singlet), d (doublet), t (triplet), q 
(quartet), dd (doublet of doublets), and m (multiplet). HPLC was 
carried out on a DIONEX summit P580 quaternary low-pressure 
gradient pump with a built-in vacuum degasser using a Summit UVD 
170s UV/vis multichannel detector. Solvents were used as HPLC 
grade. Chromeleon software was used to visualize and process the 
obtained chromatograms. Analytical separations used a flow rate of 
1 mL/min, semipreparative used a flow rate of 3 mL/min, and 
preparative used a flow rate of 20 mL/min. All tested compounds had 
a purity of ≥95% unless otherwise stated (see Supporting 
Information). 
 (S)-methyl 2-((S)-2-((tert-butoxycarbonyl)amino)-3-(4-
hydroxyphenyl)propanamido)-4-methylpentanoate (3). To a 
stirring, colorless solution of Boc-L-tyrosine 2 (125 mg, 0.444 mmol), 
in dry THF (5 mL), was added PyBOP (277 mg, 0.532 mmol), L-leucine 
methyl ester hydrochloride (162 mg, 0.889 mmol) and triethylamine 
(0.19 mL, 1.332 mmol). The white suspended solution was stirred at 
room temperature for eight hours under an argon atmosphere. After 
reaction completion, the orange solution was concentrated under 
reduced pressure and diluted with water (50 mL), where the product 
was extracted with ethyl acetate (3x50 mL). The combined organic 
layers were concentrated to 50 mL and washed with water (1x50 mL) 
and brine (1x50 mL), dried with MgSO4, filtered and concentrated 
under reduced pressure to afford a colorless oil. Flash column 
chromatography (2:1 ethyl acetate: hexane) was utilized to purify the 
product and yield dipeptide 3 as a white crystalline solid (170 mg, 
94%). 1H NMR (500 MHz, CDCl3) δ = 7.03 (d, J = 8.2 Hz, 2H), 6.73 (d, J 
= 8.5 Hz, 2H), 6.48 (s, 1H), 6.34 (d, J = 8.2 Hz, 1H), 5.11 (s, 1H), 4.60 – 
4.50 (m, 1H), 4.28 (s, 1H), 3.69 (s, 3H), 2.97 (d, J = 6.8 Hz, 2H), 1.62 – 
1.52 (m, 2H), 1.50 – 1.45 (m, 1H), 1.43 (s, 9H), 0.90 (t, J = 6.6 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ = 172.9, 171.7, 155.4, 130.4, 127.5, 
115.6, 80.5, 55.9, 52.3, 50.8, 41.4, 37.4, 28.2, 24.6, 27.7, 21.8. MS (ES) 
431.2 [M+Na]+, 331.2 [M-Boc+Na]+. 
(S)-methyl 2-((S)-2-amino-3-(4-hydroxyphenyl)propanamido)-4-
methylpentanoate (4). To a stirring solution of compound 3 (350 mg, 
0.857 mmol) in DCM (8 mL), TFA (2.5 mL) was carefully added. The 
orange solution was left to stir at room temperature for two hours. 
Upon reaction completion, the orange solution was concentrated 
under reduced pressure, diluted with water (50 mL) and neutralized 
to pH 8 with 10% NaOH. The product was extracted from the orange 
solution with ethyl acetate (4x50 mL). The combined organic layers 
were dried with MgSO4, filtered and concentrated under reduced 
pressure to yield peptide 4 as a cream/white solid (260 mg, 99%). 1H 
NMR (500 MHz, MeOD) δ = 7.14 (d, J = 8.4 Hz, 2H), 6.79 (d, J = 8.4 Hz, 
2H), 4.52 (t, J = 7.3 Hz, 1H), 4.13 – 3.99 (m, 1H), 3.73 (s, 3H), 3.24 – 
2.87 (m, 2H), 1.75 – 1.58 (m, 3H), 0.97 (dd, J = 15.8, 6.1 Hz, 6H). 13C 
NMR (126 MHz, MeOD) δ = 172.5, 168.7, 156.8, 130.3, 124.6, 115.4, 
54.4, 50.9, 40.2, 36.5, 24.5, 21.8, 20.4. MS (ES) m/z 317.1 [M+Na]+, 
295.1 [M+H]+.  
(S)-2-((S)-2-(4-cyanobenzamido)-3-(4-
hydroxyphenyl)propanamido)-4-methylpentanoic acid (5). 
Compound 4 (118 mg, 0.382 mmol) was dissolved in THF (4 mL) and 
triethylamine (0.11 mL, 0.764 mmol) and stirred under an argon 
atmosphere at room temperature for 30 minutes. To the colorless 
solution, 4-cyanobenzyl acid chloride13 (70 mg, 0.421 mmol) in THF 
(2 mL) was added dropwise and left to stir overnight at room 
temperature. The cream solution, with a suspension of white 
precipitate, was concentrated under reduced pressure and then 
diluted in water (20 mL), where the product was extracted with ethyl 
acetate (3x20mL). The combined orange organic layers were washed 
with water (20 mL) and brine (20 mL), dried with MgSO4, filtered and 
concentrated under reduced pressure to afford an orange oil. 
Column chromatography (2:1 ethyl acetate: hexane) was used to 
yield dipeptide 5 as white crystals (70 mg, 42%). 1H NMR (300 MHz, 
CDCl3) δ = 7.84 (d, J = 8.5 Hz, 2H), 7.73 (d, J = 8.5 Hz, 2H), 7.13 (d, J = 
8.5 Hz, 2H), 7.04 (d, J = 7.5 Hz, 1H), 6.75 (d, J = 8.5 Hz, 2H), 6.07 (d, J 
= 7.9 Hz, 1H), 5.49 (s, 1H), 4.87 – 4.76 (m, 1H), 4.59 – 4.49 (m, 1H), 
3.75 (s, 3H), 3.12 (ddd, J = 21.6, 13.9, 6.7 Hz, 2H), 1.58 – 1.39 (m, 3H), 
0.89 (d, J = 5.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 172.8, 171.2, 
165.5, 155.3, 137.4, 132.4, 130.5, 127.9, 122.3, 117.9, 115.6, 55.0, 
52.5, 51.2, 41.2, 37.8, 24.8, 22.6, 21.9. MS (ES) m/z 460.2 [M+Na]+. 
Methyl ((S)-3-(4-((bis(dimethylamino)phosphoryl)oxy)phenyl)-2-
(4-cyanobenzamido)propanoyl)-L-leucinate (6) To a stirring solution 
of compound 5 (100 mg, 0.229 mmol), under a nitrogen atmosphere 
in anhydrous THF (20 mL), was added N,N,N',N'-
tetramethylphosphorodiamidic chloride (0.07 mL, 0.457 mmol), 
DMAP (56 mg, 0.457 mmol) and DBU (0.05 mL, 0.344 mmol). The 
orange solution was stirred at room temperature overnight. Upon 
reaction completion the mixture was quenched with methanol (10 
mL) and stirred for 10 minutes. The solvent was then removed under 
reduced pressure and the resultant orange oil was subjected to silica 
flash column chromatography (3:97 methanol: DCM) to isolate 
diamidate 6 as a white solid (65 mg, 50%). 1H NMR (500 MHz, CDCl3) 
δ = 7.79 (d, J = 8.4 Hz, 2H), 7.65 (d, J = 7.6 Hz, 1H), 7.62 (d, J = 8.4 Hz, 
2H), 7.18 (d, J = 8.5 Hz, 2H), 7.06 (d, J = 7.8 Hz, 2H), 7.02 (d, J = 7.9 Hz, 
1H), 4.89 (q, J = 6.9 Hz, 1H), 4.55 (td, J = 8.5, 5.3 Hz, 1H), 3.73 (s, 3H), 
3.11 (ddd, J = 35.6, 14.1, 6.7 Hz, 2H), 2.69 (dd, J = 15.7, 10.1 Hz, 12H), 
1.68 – 1.56 (m, 2H), 1.53 (ddd, J = 12.0, 9.0, 4.5 Hz, 1H), 0.87 (dd, J = 
6.1, 4.7 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ = 172.8, 170.8, 165.5, 
150.3, 137.7, 132.5, 132.2, 130.7, 127.9, 120.2, 118.0, 115.1, 54.8, 
52.3, 51.1, 41.1, 37.1, 36.7, 24.8, 22.7, 21.8. 31P NMR (202 MHz, 
CDCl3) δ = 15.79. MS (ES) m/z 594.3 [M+Na]+. 
Methyl ((S)-2-(4-cyanobenzamido)-3-(4-
(phosphonooxy)phenyl)propanoyl)-L-leucinate (7) A stirring 
solution of diamidate  6 (60 mg, 0.102 mmol) in 9:1 TFA (9 mL): H2O 
(1 mL) was stirred overnight at ambient temperature. Upon reaction 
completion, the solvent was removed to afford a cream solid. The 
solid was further dried under vacuum until constant weight, yielding 
acid 7 as a white solid (40 mg, 76%). The compound was used without 
purification. 1H NMR (500 MHz, MeOD) δ = 7.74 (d, J = 8.1 Hz, 2H), 
7.70 (d, J = 8.1 Hz, 2H), 7.15 (d, J = 7.2 Hz, 2H), 7.05 (d, J = 7.6 Hz, 2H), 
4.39 (dd, J = 9.4, 5.6 Hz, 1H), 3.86 – 3.75 (m, 1H), 3.60 (s, 3H), 3.01 
(ddd, J = 23.9, 14.3, 7.5 Hz, 2H), 1.62 (dd, J = 12.5, 6.6 Hz, 1H), 1.58 – 
1.50 (m, 2H), 0.83 (dd, J = 22.1, 6.5 Hz, 6H). 13C NMR (126 MHz, 
MeOD) δ = 173.0, 172.4, 167.1, 138.2, 132.1, 132.0, 131.9, 129.7, 
128.0, 120.0, 117.6, 114.7, 55.2, 51.4, 50.9, 40.1, 36.5, 24.5, 21.9, 
20.4. 31P NMR (202 MHz, MeOD) δ = -4.34. MS (ES) m/z 516.3 [M-H]-
. HRMS C24H27N3O8NaP calcd. 516.1541 [M-H]-, found 516.1541. 
Naphthalen-1-yl phosphorodichloridate (9). In a flame dried flask, 
POCl3 (0.56 mL, 6.588 mmol) was added to a solution of 1-naphthol 
(864 mg, 6 mmol) in dry diethyl ether (6 mL). The colorless solution 
was stirred at room temperature for 30 minutes under an 
atmosphere of argon. The solution was then cooled to -78 oC, where 
triethylamine (0.84 mL, 6.588 mmol) was added dropwise and then 
allowed to stir for 30 minutes, before being left to stir for one hour 
at room temperature. The white precipitate was filtered out of the 
solution and washed with diethyl ether. The yellow filtrate was 
concentrated under reduced pressure to afford phosphorochloridate 
9 as a yellow oil (1.54 g, 98%), which was used without purification. 
Methyl (chloro(naphthalen-1-yloxy)phosphoryl)-L-alaninate (10). 
To a stirring solution of compound 9 (513 mg, 1.974 mmol) and dry 
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DCM (5 mL), in a flame dried flask, was added L-alanine methyl ester 
hydrochloride (250 mg, 1.792 mmol) and stirred for 15 minutes at 
room temperature, under an argon atmosphere. Triethylamine (0.5 
mL, 3.585 mmol) was added dropwise to the yellow solution at -78oC 
to form a suspended white precipitate. The reaction mixture was 
stirred for 30 minutes before being left to stir and warm to room 
temperature for 2.5 hours. Upon reaction completion, the 
grey/white solution was concentrated under reduced pressure and 
filtered with ether. The yellow filtrate was concentrated under 
reduced pressure to afford a yellow oil, which was purified with 
column chromatography (6:4 ethyl acetate: hexane) to yield 
phosphoramidate 10 as a yellow oil (411 mg, 70%). 1H NMR (300 
MHz, CDCl3) δ = 8.10 – 8.02 (m, 1H), 7.88 (d, J = 7.5 Hz, 1H), 7.74 (d, J 
= 8.2 Hz, 1H), 7.64 – 7.50 (m, 3H), 7.44 (t, J = 7.9 Hz, 1H), 4.45 – 4.24 
(m, 2H), 3.79 (d, J = 14.2 Hz, 3H), 1.55 (dd, J =9.2, 5.3 Hz, 3H). 31P NMR 
(121 MHz, CDCl3) δ = 8.2, 7.9. 
Isopropyl (chloro(naphthalen-1-yloxy)phosphoryl)-L-alaninate (11) 
To a stirring solution of compound 9 (513 mg, 1.97 mmol) and dry 
DCM (5 mL), in a flame dried flask, was added L-alanine isopropyl 
ester hydrochloride (300 mg, 1.794 mmol) and stirred for 15 minutes 
at room temperature, under an argon atmosphere. Triethylamine 
(0.5 mL, 3.581 mmol) was added dropwise to the yellow solution at -
78oC to form a suspended white precipitate. The reaction mixture 
was stirred for 30 minutes before being left to stir and warm to room 
temperature for 2.5 hours. Upon reaction completion, the 
grey/white solution was concentrated under reduced pressure and 
filtered with ether. The yellow filtrate was concentrated under 
reduced pressure to afford a yellow oil, which was purified with 
column chromatography (6:4 ethyl acetate: hexane) to yield 
compound 11 as a yellow oil (504 mg, 72%). 1H NMR (300 MHz, CDCl3) 
δ = 8.07 (dd, J = 6.9, 4.7 Hz, 1H), 7.87 (t, J = 3.0 Hz, 1H), 7.74 (d, J = 
8.3 Hz, 1H), 7.62 – 7.51 (m, 3H), 7.44 (t, J = 8.0 Hz, 1H), 5.09 (tt, J = 
17.1, 6.3 Hz, 1H), 4.47 – 4.16 (m, 2H), 1.54 (t, J = 6.5 Hz, 3H), 1.32 – 
1.24 (m, 6H). 31P NMR (121 MHz, CDCl3) δ = 8.3, 7.9. 
Benzyl (chloro(naphthalen-1-yloxy)phosphoryl)-L-
alaninatealaninate (12) To a stirring solution of compound 9 (513 
mg, 1.972 mmol) and dry DCM (5 mL), in a flame dried flask, was 
added L-alanine benzyl ester hydrochloride (386 mg, 1.794 mmol) 
and stirred for 15 minutes at room temperature, under an argon 
atmosphere. Triethylamine (0.5 mL, 3.583 mmol) was added 
dropwise to the yellow solution at -78oC to form a suspended white 
precipitate. The reaction mixture was stirred for 30 minutes before 
being left to stir and warm to room temperature for 2.5 hours. Upon 
reaction completion, the grey/white solution was concentrated 
under reduced pressure and filtered with ether. The yellow filtrate 
was concentrated under reduced pressure to afford a yellow oil, 
which was purified with column chromatography (6:4 ethyl acetate: 
hexane) to yield compound 12 as a yellow oil (700 mg, 97%). 1H NMR 
(300 MHz, CDCl3) δ = 8.09 – 7.98 (m, 1H), 7.87 (dd, J = 7.8, 3.5 Hz, 1H), 
7.73 (d, J = 8.3 Hz, 1H), 7.61 – 7.52 (m, 3H), 7.44 (d, J = 7.9 Hz, 1H), 
7.40 – 7.30 (m, 5H), 5.18 (dd, J = 16.4, 11.9 Hz, 2H), 4.44 – 4.23 (m, 
2H), 1.56 (t, J = 6.6 Hz, 3H). 31P NMR (121 MHz, CDCl3) δ = 8.1, 7.8. 
Methyl ((2S)-2-(4-cyanobenzamido)-3-(4-(((((S)-1-methoxy-1-
oxopropan-2-yl)amino)(naphthalen-1-
yloxy)phosphoryl)oxy)phenyl)propanoyl)-L-leucinate (13) In a 
flame dried flask, a solution of compound 5 (100 mg, 0.229 mmol) in 
dry DCM (3 mL) was stirred with dry triethylamine (0.07 mL, 0.504 
mmol) at room temperature for 15 minutes under an argon 
atmosphere. Phosphorochloridate 10 (113 mg, 0.344 mmol) was 
added dropwise in DCM (2 mL). The yellow solution was stirred at 
room temperature for 5 hours; where it was then concentrated 
under reduced pressure to form a dense yellow oil. The oil was 
diluted in water (20 mL) and the product was extracted with ethyl 
acetate (3x20 mL), where the yellow combined organic layers were 
washed with water (20 mL) and brine (20 mL), dried with MgSO4, 
filtered and concentrated to form a white solid. Column 
chromatography (2:1 ethyl acetate: hexane) was used to isolate 
prodrug 13 as white crystals (120 mg, 72%). 1H NMR (400 MHz, CDCl3) 
δ = 8.00 (dd, J = 12.5, 6.6 Hz, 1H), 7.83 (dd, J = 10.6, 7.8 Hz, 1H), 7.72 
(dd, J = 14.6, 7.8 Hz, 2H), 7.65 (dd, J = 8.0, 4.7 Hz, 1H), 7.57 – 7.43 (m, 
5H), 7.41 – 7.30 (m, 1H), 7.22 – 7.04 (m, , 4H), 6.94 (d, J = 7.9 Hz, 1H), 
4.97 – 4.82 (m, 2H), 4.55 (dd, J = 13.1, 8.1 Hz, 1H), 4.50 – 4.40 (m, 
1H), 4.25 – 4.09 (m, 1H), 3.67 (d, J = 6.4 Hz, 3H), 3.57 (d, J = 16.3 Hz, 
3H), 3.23 – 3.01 (m, 2H), 1.67 – 1.43 (m, 3H), 1.36 (dd, J = 22.2, 7.0 
Hz, 3H), 0.82 (d, J = 5.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 173.6, 
172.9, 170.9, 165.4, 149.7, 146.5, 137.4, 134.8, 133.6, 133.5, 132.2, 
130.7, 127.9, 126.7, 126.5, 125.56, 125.4, 125.0, 121.4, 120.4, 118.0, 
114.9, 54.8, 52.4, 51.0, 50.5, 41.2, 37.4, 37.0, 24.8, 22.6, 22.0, 20.8. 
31P NMR (121 MHz, CDCl3) δ = -2.5, -2.6. MS (ES) m/z 751.4 [M+Na]+. 
HRMS C38H41N4O9NaP calcd. 751.2509 [M+Na]+, found 751.2513. 
Methyl ((2S)-2-(4-cyanobenzamido)-3-(4-(((((S)-1-isopropoxy-1-
oxopropan-2-yl)amino)(naphthalen-1-
yloxy)phosphoryl)oxy)phenyl)propanoyl)-L-leucinate (14) In a 
flame dried flask, a solution of compound 5 (70 mg, 0.160 mmol) in 
DCM (5 mL) was stirred with triethylamine (0.05 mL, 0.352 mmol) at 
room temperature for 15 minutes under an argon atmosphere. 
Compound 11 (252 mg, 0.708 mmol) was added dropwise in DCM (3 
mL). The yellow solution was stirred at room temperature for 5 
hours; where it was then concentrated under reduced pressure to 
form a dense yellow oil. The oil was diluted in water (20 mL) and the 
product was extracted with ethyl acetate (3x20 mL), where the 
yellow oil was washed with water (20 mL) and brine (20 mL), dried 
with MgSO4, filtered and concentrated to form a white solid. Column 
chromatography (2:1 ethyl acetate: hexane) was used to isolate 
prodrug 14 as white crystals (110 mg, 91%). 1H NMR (400 MHz, CDCl3) 
δ = 8.01 (dd, J = 8.0, 5.3 Hz, 1H), 7.87 – 7.80 (m, 1H), 7.74 (dd, J = 9.8, 
8.5 Hz, 2H), 7.65 (d, J = 8.3 Hz, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.53 (t, J 
= 3.1 Hz, 1H), 7.52 – 7.44 (m, 3H), 7.41 – 7.35 (m, 2H), 7.23-7.12 (m, 
4H), 6.64 (dd, J = 46.4, 8.1 Hz, 1H), 5.04 – 4.78 (m, 2H), 4.62 – 4.50 
(m, 1H), 4.23 (dd, J = 12.3, 9.8 Hz, 1H), 4.17 – 4.07 (m, 1H), 3.68 (d, J 
= 9.2 Hz, 3H), 3.13 (t, J = 5.8 Hz, 2H), 1.65 – 1.43 (m, 3H), 1.38 – 1.31 
(m, 3H), 1.25 (dd, J = 17.7, 7.3 Hz, 1H), 1.20 – 1.06 (m, 6H), 0.83 (d, J 
= 2.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 172.8, 170.5, 165.3, 
149.9, 146.6, 137.5, 134.8, 133.6, 133.2, 132.3, 130.8, 127.8, 126.6, 
126.4, 125.5, 125.0, 121.4, 120.5, 118.0, 115.2, 115.0, 69.4, 54.8, 
52.4, 51.0, 50.6, 41.3, 37.5, 37.1, 24.8, 22.6, 21.8, 21.6, 21.0. 31P NMR 
(121 MHz, CDCl3) δ = -2.5, -2.5. MS (ES) m/z 757.3 [M+H]+, 779.3 
[M+Na]+. HRMS C40H45N4O9NaP calcd. 779.2822 [M+Na]+, found 
779.2825. 
Methyl ((2S)-3-(4-(((((S)-1-(benzyloxy)-1-oxopropan-2-
yl)amino)(naphthalen-1-yloxy)phosphoryl)oxy)phenyl)-2-(4-
cyanobenzamido)propanoyl)-L-leucinate (15) In a flame dried flask, 
a solution of compound 5 (70 mg, 0.160 mmol) in DCM (5 mL) was 
stirred with triethylamine (0.05 mL, 0.352 mmol) at room 
temperature for 15 minutes under an argon atmosphere. Compound 
12 (350 mg, 0.867 mmol) was added dropwise in DCM (3 mL). The 
yellow solution was stirred at room temperature for 5 hours; where 
it was then concentrated under reduced pressure to form a dense 
yellow oil. The oil was diluted in water (20 mL) and the product was 
extracted with ethyl acetate (3x20 mL), where the yellow oil was 
washed with water (20 mL) and brine (20 mL), dried with MgSO4, 
filtered and concentrated to form a white solid. Column 
chromatography (2:1 ethyl acetate: hexane) was used to isolate 
prodrug 15 as white crystals (120 mg, 93%). 1H NMR (400 MHz, CDCl3) 
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δ = 7.99 (t, J = 7.8 Hz, 1H), 7.83 (t, J = 8.3 Hz, 1H), 7.72 (dd, J = 11.7, 
8.5 Hz, 2H), 7.67 – 7.59 (m, 1H), 7.53 (d, J = 8.5 Hz, 2H), 7.50 – 7.39 
(m, 3H), 7.38 – 7.31 (m, 1H), 7.30 – 7.19 (m, 5H), 7.18 – 7.04 (m, 4H), 
6.81 (dd, J = 59.9, 8.1 Hz, 1H), 5.00 (q, J = 12.2 Hz, 2H), 4.92 – 4.80 
(m, 2H), 4.56 (dd, J = 8.5, 4.4 Hz, 1H), 4.39 (dd, J = 12.4, 10.0 Hz, 1H), 
4.30 – 4.12 (m, 1H), 3.66 (d, J = 7.0 Hz, 3H), 3.19 – 3.02 (m, 2H), 1.65 
– 1.45 (m, 3H), 1.37 (dd, J = 22.5, 7.1 Hz, 3H), 1.29 – 1.23 (m, 1H), 
0.83 (d, J = 5.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ = 172.9, 170.7, 
165.3, 149.8, 146.5, 137.5, 135.1, 134.7, 133.4, 132.3, 130.8, 128.6, 
128.5, 128.1, 127.8, 126.7, 126.6, 126.4, 125.5, 125.4, 125.0, 121.4, 
120.4, 118.0, 115.1, 67.2, 54.9, 52.4, 51.0, 50.5, 41.2, 37.4, 36.9, 24.8, 
22.6, 21.8, 20.9. 31P NMR (121 MHz, CDCl3) δ = -2.5, -2.6. MS (ES) m/z 
827.3 [M+Na]+. HRMS C44H45N4O9NaP calcd. 827.2822 [M+Na]+, 
found 827.2826. 
Serum stability of prodrug 14. Procedure was adapted from 
Slusarczyk et al.15 Compound 14 (5mg) was dissolved in DMSO (0.15 
mL) and D2O (0.15 mL) in an NMR tube. A 31P-NMR of the sample was 
initially undertaken as a control. Defrosted human serum (0.3 mL) 
was added to the NMR tube, which initially formed a cloudy solution. 
Additional DMSO (0.15 mL) was treated to aid solubility. The tube 
was then incubated at 37 °C and the spectra were recorded at 30 
min after the addition and then at even time intervals over 12 hr. At 
the end of the 31P-NMR experiment, the organics were extracted 
from the serum with ethyl acetate (3x1 mL), dried with MgSO4, 
filtered and concentrated under reduced pressure to yield a white 
solid. A 31P-NMR of this in DMSO (0.15 mL) and D2O (0.15 mL) was 
taken and this demonstrated the retention of the prodrug singlet 
pair. The extract was additionally used for LCMS.  
Cell Assay and Immunoblotting. MDA-MB-468 cells were cultured in 
RPMI 1640 media (Gibco) supplemented with 10% Fetal Bovine 
Serum (FBS) (Gibco) and 1% of PenStrep (Gibco). The cell was 
maintained at 37 °C with 5% CO2 incubator to reach 70-80% 
confluency to be used in the experiment. The cells were treated with 
ISS-610, ISS-610-Met, or prodrugs 13-15 in various concentrations 
(0.1, 1, 10, 30 and 100 µM) for 24 hours.  Protein lysates were 
prepared using 1% NP40 lysis buffer containing 50mM Tris-HCl pH 
7.5, 1mM EDTA, 1mM EGTA, 1% Nonidet-40, 0.27 M Sucrose, 1 mM 
sodium orthovanadate, 50 mM sodium fluoride, 5 mM sodium 
pyrophosphate supplemented with 1 mM benzamidine and 0.1 mM 
PMSF. Protein concentrations were measured using Bradford assay 
and SDS samples were prepared by boiling the protein sample at 90 
°C for 5 minutes in SDS sample loading buffer. 20 µg of each sample 
was loaded per lane and subjected to separation in polyacrylamide 
gels and transfer on to nitrocellulose membrane. Membranes were 
blocked in 10% skim milk in TBST [50 mM Tris/HCl (pH 7.5), 0.15 M 
NaCl containing 0.25% Tween-20] for 30 minutes at room 
temperature. The membranes were then incubated with the primary 
antibodies STAT3 (Cell Signalling Technology, #4904), Survivin (Cell 
Signalling Technology, #2808), Bcl-xl (Cell Signalling Technology, 
#2764) and β-actin (Cell Signalling Technology, #3700), overnight at 
4 °C and secondary antibodies: anti-rabbit (Cell Signalling 
Technology, #7074) or anti-mouse (Cell Signalling Technology, 
#7076), for 1 hr at room temperature. Finally, protein detection using 
horseradish peroxidase-conjugated secondary antibodies and the 
ECL® reagent (Amersham Bioscience) was performed.  
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